Yuanyuan Sun

Yuanyuan Sun

Auto-generated profile, based on publicly available information

Yuanyuan Sun

Department of Neurosurgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Purpose: High-grade glioma is the most aggressive form of primary brain tumor, characterized by rapid progression and a grim prognosis. The presence of mutations in IDH1 and TP53 is associated with a specific molecular phenotype in glioma, and their interaction is a potential target for therapy. Experimental Design: Our study utilized a combination of bioinformatics analysis, in vitro experiments, and in vivo tumor xenograft models to investigate the role of the ubiquitin-conjugating enzyme 2T (UBE2T) in the malignant progression of IDH1/TP53-mutant glioma. Results: We found that UBE2T is overexpressed in the context of TP53 mutations and is linked to enhanced glioma cell proliferation and stemness. Mechanistically, UBE2T was shown to degrade HP1α via the ubiquitin–proteasome pathway, leading to the release of the suppressive effects of R-2-hydroxyglutarate on nucleolar function and an increase in rDNA transcription. The therapeutic potential of targeting UBE2T is underscored by the discovery that APR-246, a mutant p53 reactivator, effectively suppresses UBE2T expression and reverses the hyperactivity of nucleolar transcription. Conclusions: These findings suggest that UBE2T plays a crucial role in the progression of IDH1/TP53-mutant astrocytoma and that targeting UBE2T with APR-246 could be a promising therapeutic strategy for patients with these mutations. Our study provides a foundation for further research into the role of UBE2T in glioma and the development of targeted therapies.

15 September 2025
Verified
Other
Open access
PDF file
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Supplementary Figure S5: Expression and distribution of putative UBE2T interacting E3 ubiquitin ligases.

15 September 2025
Verified
Other
Open access
PDF file
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Supplementary Figure S6: R-2HG inhibits the proliferation of IDH1 wild-type glioma cells.

15 September 2025
Verified
Other
Open access
PDF file
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Supplementary Figure S2: Supplementary data on glioma public databases and tissue samples.

15 September 2025
Verified
Other
Open access
PDF file
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Supplementary Figure S4: iTRAQ and RNA-seq analysis.

15 September 2025
Verified
Other
Open access
PDF file
FZFengqi Zhou
Fengqi Zhou
YSYuanyuan Sun
Yuanyuan Sun
XCXinhua Chen
Xinhua Chen
DWDi Wu
Di Wu
ZTZhennan Tao
Zhennan Tao
TYTianfu Yu
Tianfu Yu
Supplementary Table S2. Primers used for ChIP assay.